Immune Regulation: changing the course of disease

IRL201805 (‘1805) clinical impact

Prevalence of doctor-diagnosed arthritis in the US is estimated at 22.7% (54.4 million) of adults during 2013-2015, with significantly higher age-adjusted prevalence in women (23.5%) than in men (18.1%).15

The impact of arthritis on individuals is significant: approximately 43.5% (23.7 million) of these patients are limited in their usual activities due to their arthritis.

With the aging of the US population, arthritis prevalence is expected to increase: by 2040, it is estimated that 25.9% of the projected total adult population will have doctor-diagnosed arthritis, with 11.4% of all US adults reporting arthritis-attributable activity limitations.16

 

 

Current treatments have limitations:

Market positioning for ‘1805:

 

An orphan drug indication in juvenile rheumatoid arthritis has been identified, which could give significant benefit in terms of time to market and commercial exclusivity. ‘1805 also appears to have activity in other inflammatory and immune-system mediated diseases. Preclinical work has shown activity in inflammatory bowel disease, transplant rejection and joint loosening.